Claims

1. Use of tandospirone or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy in Parkinson's disease, wherein the medicament is to be parenterally administered.

2. The use of claim 1, wherein the parenteral administration is selected from transdermal administration, intradermal administration, subcutaneous administration, intramuscular administration, and a combination thereof.

3. The use of claim 1 or claim 2, wherein the parenteral administration has sustainability or is to be sustainably administered.

4. The use of any one of claims 1 to 3, wherein the parenteral administration comprises transdermal administration.

5. The use of any one of claims 1 to 4, wherein the motor complications comprise levodopa induced dyskinesia (PD-LID).

6. Use of tandospirone or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating, improving, or preventing motor complications associated with levodopa therapy in Parkinson's disease, wherein levodopa induced dyskinesia (PD-LID) is improved without resulting in a rebound symptom, and wherein the medicament is to be transdermally administered.

7. The use of claim 6, wherein levodopa induced dyskinesia (PD-LID) comprises peak-dose dyskinesia, diphasic dyskinesia, and a combination thereof.

8. The use of claim 6 or claim 7, wherein the treatment, improvement, or prevention of motor complications comprises improvement, or prevention of levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof.

9. Use of tandospirone or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for accomplishing improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof, wherein the medicament is to be parenterally administered.

10. The use of claim 9, wherein the improvement of levodopa induced dyskinesia (PD-LID) symptom is a clinically significant improvement or greater.

11. The use of claim 9 or claim 10, wherein the improvement levodopa induced dyskinesia (PD-LID) symptom is to a sufficient level to attain a clinical effect.

12. The use of any one of claims 9 to 11, wherein the medicament is a transdermally administrable formulation.

13. The use of any one of claims 9 to 12, wherein the medicament is an adhesive formulation.

14. The use of claim 12 or claim 13, wherein the transdermally administerable formulation is a tape/patch.

15. The use of any one of claims 9 to 14, wherein a drug dosage of the tandospirone or a pharmaceutically acceptable salt thereof is 0.1 to 100 mg per day as a free form of tandospirone.

16. The use of any one of claims 9 to 15, wherein an amount of drug penetration for the tandospirone or a pharmaceutically acceptable salt thereof is 0.1 to 20 mg per day as a free form of tandospirone.

17. The use of any one of claims 12 to 16, wherein the total applied area per dose of the transdermally administrable formulation of the medicament is 1 to 100 cm^2.

18. The use of any one of claims 9 to 17, wherein the medicament is to be administered such that a human blood (plasma)/tandospirone concentration of 0.05 to 20 ng/mL is maintained for 12 hours or longer per day.

19. The use of any one of claims 9 to 18, wherein the medicament is to be administered such that a human blood (plasma)/tandospirone concentration of 0.05 to 20 ng/mL is maintained for 8 to 16 hours after administration of the medicament.

20. The use of any one of claims 9 to 19, wherein the medicament is an adjunct of levodopa.

21. The use of any one of claims 9 to 20, which is to be used with levodopa as the fixed-dose combination or concomitantly as separate formulations.

22. Use of tandospirone or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving the exacerbation in quality of response to levodopa therapy of a Parkinson’s disease patient with dyskinesia wherein the medicament is to be parenterally administered.

23. The use of any one of claims 1 to 22, wherein the tandospirone or a pharmaceutically acceptable salt thereof in the medicament is a free form of tandospirone.